Literature DB >> 21045296

Purification, crystallization and preliminary X-ray analysis of a fusion of the LIM domains of LMO2 and the LID domain of Ldb1.

Kamel El Omari1, Catherine Porcher, Erika J Mancini.   

Abstract

LMO2 (LIM domain only 2), also known as rhombotin-2, is a transcriptional regulator that is essential for normal haematopoietic development. In malignant haematopoiesis, its ectopic expression in T cells is involved in the pathogenesis of leukaemia. LMO2 contains four zinc-finger domains and binds to the ubiquitous nuclear adaptor protein Ldb1 via the LIM-interaction domain (LID). Together, they act as scaffolding proteins and bridge important haematopoietic transcription factors such as SCL/Tal1, E2A and GATA-1. Solving the structure of the LMO2:Ldb1-LID complex would therefore be a first step towards understanding how haematopoietic specific protein complexes form and would also provide an attractive target for drug development in anticancer therapy, especially for T-cell leukaemia. Here, the expression, purification, crystallization and data collection of a fusion protein consisting of the two LIM domains of LMO2 linked to the LID domain of Ldb1 via a flexible linker is reported. The crystals belonged to space group C2, with unit-cell parameters a = 179.9, b = 51.5, c = 114.7 Å, β = 90.1°, and contained five molecules in the asymmetric unit. Multiple-wavelength anomalous dispersion (MAD) data have been collected at the zinc X-ray absorption edge to a resolution of 2.8 Å and the data were used to solve the structure of the LMO2:Ldb1-LID complex. Refinement and analysis of the electron-density map is in progress.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045296      PMCID: PMC3001649          DOI: 10.1107/S1744309110032872

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  28 in total

1.  SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression.

Authors:  S Herblot; A M Steff; P Hugo; P D Aplan; T Hoang
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

2.  PHENIX: building new software for automated crystallographic structure determination.

Authors:  Paul D Adams; Ralf W Grosse-Kunstleve; Li Wei Hung; Thomas R Ioerger; Airlie J McCoy; Nigel W Moriarty; Randy J Read; James C Sacchettini; Nicholas K Sauter; Thomas C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-10-21

3.  The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13.

Authors:  T Boehm; L Foroni; Y Kaneko; M F Perutz; T H Rabbitts
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

Review 4.  The diverse biofunctions of LIM domain proteins: determined by subcellular localization and protein-protein interaction.

Authors:  Quanhui Zheng; Yong Zhao
Journal:  Biol Cell       Date:  2007-09       Impact factor: 4.458

5.  The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development.

Authors:  A J Warren; W H Colledge; M B Carlton; M J Evans; A J Smith; T H Rabbitts
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

6.  The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells.

Authors:  G G Grütz; K Bucher; I Lavenir; T Larson; R Larson; T H Rabbitts
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

7.  Tandem LIM domains provide synergistic binding in the LMO4:Ldb1 complex.

Authors:  Janet E Deane; Daniel P Ryan; Margaret Sunde; Megan J Maher; J Mitchell Guss; Jane E Visvader; Jacqueline M Matthews
Journal:  EMBO J       Date:  2004-09-02       Impact factor: 11.598

8.  An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions.

Authors:  C-H Nam; M N Lobato; A Appert; L F Drynan; T Tanaka; T H Rabbitts
Journal:  Oncogene       Date:  2008-04-28       Impact factor: 9.867

9.  TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3.

Authors:  Y Ono; N Fukuhara; O Yoshie
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

10.  Solving structures of protein complexes by molecular replacement with Phaser.

Authors:  Airlie J McCoy
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-12-13
View more
  3 in total

Review 1.  LMO2 at 25 years: a paradigm of chromosomal translocation proteins.

Authors:  Jennifer Chambers; Terence H Rabbitts
Journal:  Open Biol       Date:  2015-06       Impact factor: 6.411

2.  Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets.

Authors:  Kamel El Omari; Sarah J Hoosdally; Kapil Tuladhar; Dimple Karia; Elisa Hall-Ponselé; Olga Platonova; Paresh Vyas; Roger Patient; Catherine Porcher; Erika J Mancini
Journal:  Cell Rep       Date:  2013-07-03       Impact factor: 9.423

3.  Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2.

Authors:  Leanne Milton-Harris; Mark Jeeves; Sarah A Walker; Simon E Ward; Erika J Mancini
Journal:  Oncotarget       Date:  2020-05-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.